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Abstract
Histidine metabolism is a key pathway physiologically involved in satiety, recogni-
tion memory, skin, and neural protection and allergic diseases. Microbiologically-
produced imidazole propionate induces type II diabetes and interferes with glu-
cose lowering drugs. Despite their determinant health implications, no single
method simultaneously assesses histidine metabolites in urine, feces, and micro-
biota. The aim of this study was to develop a simple, rapid, and sensitive method
for the determination of histidine and its major bioactive metabolites histamine,
N-acetylhistamine, imidazole-4-acetate, cis-urocanate, trans-urocanate, glutamate
and imidazole propionate, using ultrahigh-performance liquid chromatography
with electrospray ionization tandem mass spectrometry. An innovative simple
extraction method from small aliquots of human and mice urine, feces and
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microbial cell extracts was coupled to separation in a 6.5 min chromatographic
run. The successful performance allowed accurate and precise quantification of all
metabolites in mouse feces, suggesting broad exchange of histidine metabolites
between the gut and mice. Higher urine histamine, histamine to histidine ratio,
and imidazole-4-acetate pointed to an underlying inflammatory or allergic process
in mice compared to human subjects. N-acetylhistamine and imidazole propionate
were detected in human and mouse feces, confirming its origin from gut microbial
metabolism. Our novel and robust analytical method captured histidine metabo-
lism in a single assay that will facilitate broad and deep histidine metabolic
phenotyping assessing the impact of microbiota on host health in large-scale
human observational and interventional studies.
KEYWORD S
feces, histidine pathway, microbiota, UHPLC–ESI–MS/MS, urine
1 | INTRODUCTION
The gut microbiota is a dense and diverse microbial com-
munity present in the gastrointestinal tract composed
approximately by 1014–1015 bacterial cells (i.e., 10 times the
number of eukaryotic cells in the body), largely contributing
to organism health and disease in terms of their relative
genetic content. Extensive evidence has revealed that gut
microbial communities have co-evolved with the host to
develop a mutualistic relationship, influencing metabolic
homeostasis, endocrine system, brain function, and macro-
nutrient availability.1 Gut microbiota modulate several pro-
cesses along the gastrointestinal tract; playing an important
role in the extraction, synthesis, and absorption of many
nutrients and metabolites, including bile acids, lipids, short-
chain fatty acids, vitamins, and amino acids.2 Indeed, more
than 50% of the metabolites present in feces and urine are
derived from or modified by the gut microbiota.3 Specifi-
cally, the gut microbiota is not only involved in amino acid
synthesis or fermentation but in the regulation of amino
acid catabolism, even providing unique forms of amino acid
modification that yield by-products with immune, meta-
bolic, and neurologic impact.4–6
Such chemical crosstalk between the host and its gut
microbiota may also reach histidine metabolism. Histidine
is a nutritionally essential amino acid in mammals, fish,
and poultry because it is not de novo synthesized and must
be obtained through the diet.7,8 Histidine plays an impor-
tant role in anemia, erythropoiesis, hemoglobin metabo-
lism, skin lesion, malaise, anorexia, and mental charge,9
and has been shown to improve insulin sensitivity, induce
body fat loss with reduction of waist circumference, reduce
appetite, and decrease oxidative stress and plasma levels of
systemic inflammation markers.10
Dysfunction of the histidine pathway has been linked
to vascular, dermatological, metabolic, digestive, immu-
nological, and neurological disorders (Figure 1). Hista-
mine is a biogenic amine synthesized from histidine by
the action of histidine decarboxylase (HDC). Histamine is
a neurotransmitter with roles in gastric secretions and
colonic motility and in multiple central nervous system
disorders including insomnia, narcolepsy, Parkinson's dis-
ease, schizophrenia, Alzheimer's disease, and cerebral ische-
mia. Additionally, histamine shows both pro-inflammatory
and anti-inflammatory effects on immunoregulatory pro-
cesses and is a major mediator in allergic diseases.11–14
Histamine is further oxidized to imidazole-4-acetate, a
γ-aminobutyric acid-type A receptor agonist, and type C
receptor antagonist, whose administration to animals reduces
motor activity, enhances seizures, and allodynia and leads to
a sleep-like state with seizures.15–18 Histamine can alterna-
tively progress to N-acetylhistamine which acts as a powerful
stimulant of gastric secretion, a constrictor of bronchial
smooth muscle, a regulator of body temperature, a vasodila-
tor and a centrally acting neurotransmitter.19 Excess of die-
tary histidine is irreversibly degraded to trans-urocanate by
the rate-limiting action of histidine ammonia-lyase (HAL) or
histidase, an enzyme highly expressed in the surface layer
(stratum corneum) of the skin and in the liver.20 Trans-
urocanate can be an important intermediary in the histidine
to glutamate metabolic pathway that has been associated
with increased excitatory neurotransmission.21 In the skin,
trans-urocanate serves as a natural sunscreen since pho-
toisomerization to cis-urocanate absorbs UV radiation.22
Many in vivo and in vitro studies have revealed the local and
systemic anti-inflammatory and immunosuppressive proper-
ties of cis-urocanate, downregulating hypersensitivity
reactions, suppressing cell mediated immunity, attenuating
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sclerosis, and dextran sulfate-induced inflammatory bowel
disease and protecting cells from UV injury.23–26 In the liver,
after two reaction steps, trans-urocanate is finally converted
into glutamate, a non-essential amino acid with vital roles in
intermediary metabolism and in the biosynthesis of nucleic
acids, proteins and amino acids such as proline and arginine.
Glutamate, the most abundant amino acid in the mamma-
lian brain, acts as a major excitatory neurotransmitter
through a wide variety of receptors regulating neuroimmune
crosstalk, language, synaptic plasticity, learning, memory,
motor activity, neural development, and Alzheimer's dis-
ease.27–31 Last but not least, trans-urocanate can also be
reduced to imidazole propionate (dihydrourocanate or
deamino-histidine) by urocanate reductase, a metabolic route
provided by gut microbiota to mammals. Recently,
microbially-produced imidazole propionate has been shown
to be elevated in plasma of prediabetic and type-2 diabetic
subjects, induce type-2 diabetes via mTORC1 and reduce
glucose-lowering effects of metformin.32–34
Despite the physiological importance of histidine
and its bioactive metabolites, the lack of a standardized
and sensitive method for their simultaneous detection and
quantification hampers correct assessment of the influence
of gut ecosystem dysbiosis in large cohort disease studies.
The objective of this study was to develop a quick and
effective method to quantify the concentrations of histi-
dine and its bioactive metabolites N-acetylhistamine,
glutamate, imidazole propionate, imidazole-4-acetate, cis-
urocanate, trans-urocanate and histamine in feces, urine
and, specifically, in microbiota metabolome from healthy
infants and C57BL/6 mice. A major achievement was the
determination of histidine metabolites in a single assay
because simultaneous metabolite quantitation allows accu-
rate assessment of metabolite ratios, yielding statistically
robust associations with perturbations in pathways rather
than separate analyses of single metabolites.35 The valida-
tion was carried out by spiking the sample solutions with two
standards (atenolol and 2-amino-4-thiazoleacetic acid
[ATAA]), undetected in human and mouse biosamples.21,36
To fulfill our goal, we used ultrahigh-performance liquid
chromatography with electrospray ionization tandem mass
spectrometry (UHPLC–ESI–MS/MS) due to its ability to accu-
rately identify and quantify multiple chemical compounds.
2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
Water (18.2 MΩ cm1) was purified with a Milli-Q Plus®
system (Millipore, Madrid, Spain). The LC–MS solvent
(acetonitrile, ACN) and additive (formic acid) were of
UHPLC–MS-grade and were from Scharlau (Scharlab
S.L., Barcelona, Spain). L-glutamate, imidazole-4-acetate,
N-acetylhistamine, cis-urocanate, imidazole propionate
and 2-amino-4-thiazoleacetic acid were from Sigma-
Aldrich Chemie GmbH. Trans-urocanate, histamine, and
atenolol were obtained from Acros Organics (Geel, Belgium).
FIGURE 1 Metabolic pathways involving measured metabolites from the histidine metabolism
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L-histidine was from VWR International Ltd (UK). Other
chemicals used for measuring enzymatic activities were
BugBuster Protein Extraction Reagent (Novagen, Darmstadt,
Germany), magnesium chloride, reduced glutathione,
pyridoxal-50-phosphate and aminoguanidine (Sigma-Aldrich,
Chemie GmbH).
2.2 | Extraction protocol for metabolite
isolation
2.2.1 | Human and mouse samples
Ten healthy full-term infants aged 6-months, who did not
present any intestinal disorders and had not taken antibi-
otics, were chosen from the panel of infants that
belonged to PREOBE study cohort.37 Urine and fresh
stools were collected at 6-months after delivery and were
immediately stored at 80C, until processing. This pro-
ject followed the ethical standards recognized by the Dec-
laration of Helsinki (reviewed in Hong-Kong 1989 and in
Edinburgh 2000) and the EEC Good Clinical Practice rec-
ommendations (document 111/3976/881990), and cur-
rent Spanish legislation regulating clinical research in
humans (Royal Decree 561/1993). Also, urine and stool
samples were collected from 10 4-week-old C57BL/6
mice. Mice received human care and all experimental
protocols were approved by the institutional animal
ethics committee and performed in accordance with
national and institutional regulations.
2.2.2 | Urine preparation
Frozen urine samples were thawed and a 10 μL aliquot
was transferred by pipetting into a 1.5 mL Eppendorf
tube. Nine hundred and ninety microliters of ACN/H2O
(50/50; v/v) were added to urine samples. The tubes were
centrifuged at 13,000 rpm at 4C for 10 min. Urine super-
natants were removed, filtered through 0.2-μm nylon
syringe filters and frozen in analytical vials at 20C
until UHPLC–MS/MS analysis.
2.2.3 | Fecal and microbial intracellular
metabolites
Microbiota cells were separated from the fecal matrix by
mixing 0.1 g of fecal sample with 2 mL of 0.05%
L-cysteine phosphate saline buffer solution. Following
re-suspension (by 1 min of vigorous vortexing), the sam-
ples were then centrifuged at 500g for 1 min at 4C to
remove fecal debris. The supernatant was transferred to a
2-mL Eppendorf tube and centrifuged at 14,000g at 4C
for 1 min to pellet the cells. Five hundred microliters of
this supernatant were mixed with 500 μL of UHPLC–MS-
grade ACN to precipitate proteins. This solution was then
centrifuged at 13,000 rpm at 4C for 10 min to separate
any solid impurities. The supernatants were removed, fil-
tered through 0.22-μm nylon syringe filters and frozen in
analytical vials at 20C until UHPLC–MS/MS analysis.
Pelleted microbiota cells were resuspended in 300 μL
of phosphate saline buffer solution (PBS) and split into
two aliquots. For determination of intracellular histidine
bioactive metabolites, microbial cells were lysed with
15 consecutive freeze–thaw cycles in liquid nitrogen and
a thermoblock (28C). The samples were sonicated for
2 min on ice (Bandelin Sonopuls, HD 2070) at the 30%
amplitude setting. The final pellet was removed following
centrifugation at 14,000g for 10 min at 4C. Supernatants
were mixed with 150 μL of UHPLC–MS-grade ACN, and
centrifuged at 13,000 rpm for 10 min at 4C. The super-
natants were removed, filtered through 0.2-μm nylon
syringe filters and frozen in analytical vials at 20C
until UHPLC–MS/MS analysis.
2.3 | Measurement of microbial HAL
and HDC activities
The remaining aliquot of resuspended microbiota cells
was mixed with the same volume of BugBuster protein
extraction reagent, gently shaken for 30 min at 37C and
further disrupted by freeze–thaw cycles and sonication as
previously described. Protein extracts were centrifuged at
14,000g for 10 min at 4C to separate cell debris. Product
synthesis by the enzymes HAL and HDC were measured
in protein extracts using 1 mg mL1 histidine substrate.
HAL reactions were determined in 200 mM Tris HCl
buffer pH 9 with 10 mM MgCl2 and 100 mM GSH. HDC
reactions were measured in 80 mM sodium acetate
pH 6.5 with 61 mM pyridoxal-50-phosphate and 10 mM
aminoguanidine.
2.4 | Standard solutions and calibration
curves
Standard solutions were prepared individually in
1 mg mL1 ACN/H2O, (50/50 v/v). The same dilution sol-
vents were used for internal standards (IS) stock solutions.
Standard and IS stock solutions were stored at 20C for
up to 2 weeks. Working solutions were prepared weekly
by diluting stock solutions with the same solvent.
Calibration was built by dilution of standard stock
solutions in ACN/H2O (50/50; v/v) to obtain six solutions
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in ng mL1 range for target analytes. Each point of the
standard curve was prepared in triplicate and each
extract was analyzed three times. IS, atenolol for
urocanates and ATAA for the other analytes were
added after extraction at a final concentration of
10 ng mL1. Calibration curves were plotted using ana-
lyte/internal standard peak area ratio versus concen-
tration of analyte.
2.5 | Instrumentation and analytical
conditions
A high-throughput method was developed using UHPLC–
ESI–MS/MS. All measurements were completed in the Cen-
tre for Scientific Instrumentation (University of Granada).
Chromatography was performed with a Waters Acquity
UPLC™ System I-Class (Waters, UK). Two different ultra-
performance liquid chromatography analyses were exam-
ined: (i) generic analysis, separation was performed using
an Acquity UPLC HSS™ T3 (1.8 μm, 2.1  150 mm;
Waters) column (HSS T3 Column); and (ii) urocanate iso-
mer analysis, separation was carried out using an Acquity
ultra-performance liquid chromatography BEH™ Amide
(1.7 μm, 2.1  100 mm; Waters) column (BEH Amide Col-
umn). Instrumental parameters are shown in Table 1. In
both analytical methods, mobile phase A was 0.1% formic
acid in water, and the mobile phase was B 0.1% formic acid
in ACN. The column was used at room temperature. The
sample injection volume was 10 μL, and the flow rate was
0.3 and 0.35 mL min1, respectively. Mass spectrometry
was performed with a Waters triple quadrupole mass spec-
trometer (XevoTQ-XS, Waters, UK). The mass spectrometer
was operated in the positive ESI mode with the following
operation conditions: capillary voltage, 2.90 kV; ion source
temperature, 150 C; desolvation temperature, 600 C; deso-
lvation gas flow rate, 500 L h1; cone gas flow rate,
150 L h1. The protonated molecular ions [M + H]+ of his-
tidine bioactive metabolites were chosen as the precursor
ions, because of their highest optimization of the
TABLE 1 Transitions and optimized potentials for UHPLC–MS/MS analysis of histidine metabolites
Chemical formula tR (min) Transitions CV CE
HSS T3 column
Histidine C6H9N3O2 0.9 156.04 ! 82.33a 6 18
156.04 ! 92.48b 6 18
N-acetylhistamine C7H11N3O 1.49 154.06 ! 67.38a 4 24
154.06 ! 94.49b 4 14
Glutamate C5H9NO4 1.05 148.02 ! 101.51a 6 8
148.02 ! 83.43b 6 12
Imidazole propionate C6H7N2O2 1.49 141.09 ! 80.43a 2 18
141.09 ! 94.51b 2 10
Imidazole acetate C5H6N2O2 1.31 127.14 ! 53.30a 28 20
127.14 ! 80.38b 28 4
Histamine C5H9N3 0.83 112.11 ! 40.31a 12 18
112.11 ! 82.41b 12 8
ATAA C5H6N2O2S 1.49 159.05 ! 70,33a 4 26
159.05 !112.51b 4 22
BEH amide column
Cis-urocanate C6H5N2O2 1.5 139.07 ! 65.29a 32 18
139.07 ! 92.48b 32 16
Trans-urocanate C6H5N2O2 1.92 139.07 ! 65.29a 32 18
139.07 ! 92.48b 32 16
Atenolol C14H22N2O3 1.81 267.19 ! 144.67a 6 26
267.19 ! 189.83b 6 16
Abbreviations: CV, cone voltage (V); CE, collision energy (eV).
aMRM transition used for qualification.
bMRM transition used for quantification.
ACUÑA ET AL. 5
instrument parameters. One specific mass transition (m/z)
was selected for each analyte using the multiple reaction
monitoring mode (MRM) function of the instrument for
qualification and quantitation. The optimized compound-
dependent mass parameters (cone voltage and collision
energy) and the MRM transitions are shown in Table 1.
Chromatography details of each method and MS settings
are provided in the Supplementary Material, Tables S1 and
S2. Masslynx software version 4.2 was used for instrument
control and data acquisition. Statistical analyses were
carried out using SPSS version 26.0 (IBM SPSS, Inc.,
Chicago, IL).
2.6 | Matrix effect and validation
To check for the matrix effect for IS and consequently for
histidine bioactive metabolites, a slope comparison
between several calibration curves were performed. A
six-concentration-level curve for atenolol and ATAA in
distilled water and ACN was prepared. Similarly, a sec-
ond calibration curve was carried out by adding to every
matrix the same amount of IS as used in the standard cal-
ibration (six calibration levels).
We validated the developed method in terms of lin-
earity, limit of detection (LOD), limit of quantification
(LOQ), selectivity, accuracy (trueness and precision)
and recovery according to the US Food and Drugs
Administration (FDA) guideline for Bioanalytical
Method Validation.38 Calibration curves were prepared
by calculating the chromatographic peak area ratio of
the analyte and it IS for each metabolite at each con-
centration level. LOD is the minimum amount of com-
pound detectable in the sample, while the LOQ is the
minimum amount quantified. Both were determined in
order to check the sensitivity of the analytical method.
In this work, these parameters were calculated follow-
ing the method defined by Currie.39 We extracted their
values from the calibration function, using the stan-
dard deviation of residual, Sy/x, the slope of the curve,
b, and an estimation of the standard deviation of the
blank (S0). The LOD is defined as 3S0 and the LOQ as
10S0. Selectivity was assessed by comparing the chro-
matogram of the blank sample with the corresponding
spiked sample containing a known concentration of
the internal standards. Accuracy (trueness and preci-
sion) was assessed by spiking samples at low, medium,
and high levels (5, 50, and 100 ng mL1, respectively)
in three replicates for each compound during three
consecutive days. We used solvent blanks every 10 sam-
ples to control background contamination and we did
not find quantifiable amounts of target analytes.
3 | RESULTS AND DISCUSSION
Amino acids are one of the main building blocks of life
and are used in a variety of metabolic and physiological
forms by the gut microbiota.40 One of these amino acids,
histidine and its bioactive metabolites, have broad physio-
logical effects ranging from neurological development and
disorders to dermatologic, metabolic, digestive, vascular
and immunosuppressive effects.9–34,41 Using UHPLC–ESI–
MS/MS, we developed a novel method to simultaneously
determine histidine and seven bioactive metabolites easily
extracted from a small amount of human and mice urine,
feces and microbiota metabolome in a single rapid run
(6.5 min), enabling a comprehensive assessment of organ-
ismal histidine metabolism. We also monitored activity of
the main enzymes governing histidine metabolism, HAL
and HDC, in gut microbial cellular extracts.
3.1 | Method optimization
We employed the UHPLC–ESI–MS/MS method due to its
accuracy, selectivity, sensitivity, and reproducibility.
Although the negative mode was proved, the use of posi-
tive ESI resulted in good ionization of the compounds
and [M + H]+ ions were selected as precursor ions. Selec-
tivity and sensitivity of the method were further
improved by the choice of the product ion producing the
highest response. Different stationary phase and mobile
phase options were tested, and eventually we obtained
the best separation, peak shape, and response in an 0.1%
formic acid in water (v/v) and an ACN mobile phase in
the gradient elution mode.
We tested different C18 columns for a reverse-phase
analysis, such as Acquity HSS T3 column (1.8 μm,
2.1  150 mm) that promotes polar compound retention
and aqueous mobile-phase compatibility. When we used
HSS T3 column, histidine metabolites were well retained
but cis- and trans-urocanate isomers were split into two
broad peaks. We then tested the hydrophilic interaction
liquid chromatography (HILIC) analysis for urocanate
isomer separation. We ran the analysis on the BEH
amide column (1.7 μm, 2.1  100 mm) since this is
known to provide sufficient retention for very polar com-
pounds.42 Separation on the HILIC column was previ-
ously tested by Joo et al., and it was successfully applied
to determine the level of cis- and trans-urocanate in the
stratum corneum from forearm and forehead samples.43
We observed a sufficient separation and good peak
shapes of urocanates, but displayed a poor performance
for the other analytes. As improving separation of iso-
mers without sacrificing broad coverage was one of the
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key objectives in developing this method, we decided to
use the HSS T3 Column to detect and quantify histidine,
N-acetylhistamine, glutamate, imidazole propionate,
imidazole-4-acetate and histamine, and the BEH Amide
Column for trans- and cis-urocanate.
3.2 | Method validation
3.2.1 | Evaluation of matrix effect
Due to its high selectivity and sensitivity, mass spectrom-
etry in tandem with liquid chromatography is a powerful
analytical tool.44 However, the development of HPLC-
MS/MS instrumentation and its applications do not guar-
antee the effective elimination of interferences from
endogenous impurities. Quantitative analysis with ESI
can be substantially affected by the occurrence of ion-
suppression or -enhancement caused by the presence of a
matrix or other interferences in the sample, as reported
by many authors.44,45 This phenomenon is commonly
referred as “matrix effects (ME),” and it is responsible for
poor and unreliable data in a quantitative assay, inducing
a heavy influence in the reproducibility, linearity and
accuracy of the method.45 Matrix effects may occur in
any LC–MS analysis, especially in complex matrices such
as feces, microbial metabolome and urine. The use of IS
is a noted efficient strategy to overcome and ameliorate
matrix effects and consequently improve the accuracy of
the method.44
In the present work, we propose the use of two stan-
dards with similar structures and chemical behavior anal-
ogous to the histidine metabolites: atenolol21 for cis- and
trans-urocanate, and ATAA36 for the other metabolites.
Those compounds have never been detected in human and
mice samples and were not detected in our samples. We
spiked these two standards in human and mouse urine (HU,
MU), feces (HF, MF), and microbial metabolome (HM, MM).
To check the presence or absence of matrix effect for
atenolol or ATAA standard and consequently for the his-
tidine metabolites, a slope comparison between different
calibration curves was carried out. First, a six-concentra-
tion-level curve for atenolol and ATAA in distilled water
and ACN was prepared. In a similar way, a second cali-
bration curve was performed by adding to every matrix
the same amount of atenolol and ATAA as used in the
standard calibration (six calibration levels). Tables 2 and
3 show the obtained calibration parameters.
A t-Student test was applied to compare the statistical
similarity between the values of the slope for each cali-
bration curve.46 First, we compared the variances, esti-
mated as s2y=x by means of the Snedecor's F distribution.
The calculated F-values were lower than the critical
F value of 6.38 (significance level 5% and 4 degrees of
freedom), and variances were equal. Consequently, the
calculated t value is obtained with the equation




where b1, b2, s2b1 and s
2
b2 are the slopes of the calibration
curves and their respective variances. These values were
compared with the theoretical t-value of 2.23 and
were lower, indicating no significant differences in the
slopes and intercepts. As the response for both standards
was statistically equal, in deionized water + ACN and in
TABLE 2 Matrix effect. Comparison of calibration curves in H2O + ACN (standard) and every of the measured matrices for ATAA
ATAA Statistical comparison
a sa b (mL ng
1) sb (mL ng
1) R2 (%) sy/x Fcalc tcalc (b) tcalc (a)
Standard 580.42 965.04 728.54 18.75 99.8 1455.73
HU 14.02 1136.31 749.78 22.07 99.74 1714.08 1.39 0.73 0.38
HM 329.44 482.88 695.09 9.38 99.94 728.4 3.99 1.59 0.84
HF 1505.33 1259.14 704.96 24.46 99.64 1899.36 1.7 0.77 0.58
MU 264.78 432.32 667.86 8.4 99.95 652.14 4.98 1.05 0.8
MM 578.4 611.66 680.24 11.88 99.91 922.67 2.49 2.18 0.01
MF 311.92 1155.73 729.4 22.45 99.72 1743.38 1.43 0.03 0.18
HDC 481.05 613 688.52 11.91 99.91 924.68 2.48 1.8 0.93
HAL 484.32 812.35 685.18 15.78 99.84 1225.4 1.41 1.77 0.84
Notes: a, intercept; sa, intercept standard deviation; b, slope; sb, slope standard deviation; R
2, determination coefficient; sy/x, regression standard deviation. Ftab
(df: 4; p = 0.95) = 6.38; ttab (df: 10; p = 0.95) = 2.23.
Abbreviations: HU, human urine; HM, human microbial metabolome; HF, human feces; MU, mouse urine; MM, mouse microbial metabolome; MF, mouse
feces; HDC, histidine decarboxylase activity; HAL, histidine ammonia-lyase activity.
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every human and mouse sample, the absence of matrix
effect was demonstrated. Therefore, the histidine metabo-
lites should not present matrix effect in any of the matri-
ces measured.
3.2.2 | Analytical characteristics of the
method
Linearity of the curve calibration
Once the absence of matrix effect was demonstrated, a six
point's calibration curve was built by injecting 100 μL of dif-
ferent standard solutions. A calibration curve for each histi-
dine metabolite was constructed using analyte/internal
standard peak-area ratio vs concentration of analyte. The
results for the intercept (a), slope (b), correlation coefficient
(R2) and probability level of the lack-of-fit test, Plof (%), are
summarized in Table 4. The values of the correlation coeffi-
cients (R2) ranged from 99.6 to 100% and p values
were > 5% in all cases (Plof%).
47 Thus, the data yield shows
good linearity within the stated ranges.
Sensitivity (LOD and LOQ)
The values obtained for the LODs ranged from 0.2 to
2.4 ng mL1, and the LOQs from 0.7 to 8.2 ng mL1 for
trans-urocanate and imidazole-4-acetate, respectively.
The results are summarized in Table 4.
Selectivity
The comparison between the chromatogram of a spiked
sample containing a known concentration of the internal
standards with the corresponding to the blank sample
demonstrated that they were not present in the samples,
and interferences from endogenous substances were
absent at the retention time of all analytes. Therefore, the
optimized instrumental conditions confirmed a high
selectivity of the proposed method. Chromatograms in
MRM mode of a mouse fecal sample are shown
in Figure 2 (HSS T3 column) and Figure 3 (BEH amide
column).
Accuracy (trueness and precision)
We analyzed spiked samples at three concentration levels
(5, 50, and 100 ng mL1) in three replicates for each com-
pound in the solvent blank during three consecutive
days. Precision was calculated as relative standard devia-
tion (%RSD). Recovery rates (%Rec) were determined for
trueness by comparing the estimated concentration with
the spiked amount. Table 5 shows the results obtained. %
Rec ranged from 87% for imidazole propionate to 114%
for imidazole-4-acetate, which are within the rec-
ommended limits (±15% of nominal concentrations).38
Inter-day precision was also <15% in all cases. Therefore,
all compounds were within the acceptable limits for
bioanalytical method validation.
3.3 | Biomonitoring of histidine
bioactive metabolites in human and mouse
urine, feces, and microbiota metabolome
L-histidine is a nutritionally essential amino acid with
unique biochemical and physiological properties used to
treat rheumatoid arthritis and anemia in patients with
TABLE 3 Matrix effect
Atenolol Statistical comparison
a sa b (mL ng
1) sb (mL ng
1) R2 (%) sy/x Fcalc tcalc (b) tcalc (a)
Standard 16224.03 9527.44 8530.31 185.08 99.86 14371.82
HU 14208.95 8471.88 8622.77 164.57 99.89 12779.55 1.26 0.37 0.16
HM 5217.72 7079.89 8793.32 137.53 99.93 10679.78 1.81 1.14 1.81
HF 14549.94 5085.34 8321 98.79 99.96 7671.06 3.51 1 0.16
MU 584.73 6634.85 8862.22 128.89 99.94 10008.44 2.06 1.19 1.45
MM 4418.15 8014.02 8754.45 155.68 99.91 12088.88 1.41 0.93 1.66
MF 11680.97 5728.56 8432.22 111.28 99.95 8641.34 2.77 0.45 0.41
HDC 2062.42 6856.23 8890.06 133.19 99.93 10342.39 1.93 1.58 1.21
HAL 2797.81 7613.3 8829.67 147.89 99.92 11484.41 1.57 1.26 1.56
Notes: Comparison of calibration curves in H2O + ACN (standard) and every of the measured matrices for atenolol. a, intercept; sa, intercept standard
deviation; b, slope; sb, slope standard deviation; R
2, determination coefficient; sy/x, regression standard deviation. Ftab (df: 4; p = 0.95) = 6.38; ttab (df: 10;
p = 0.95) = 2.23.
Abbreviations: HU, human urine; HM, human microbial metabolome; HF, human feces; MU, mouse urine; MM, mouse microbial metabolome; MF, mouse
feces; HDC, histidine decarboxylase activity; HAL, histidine ammonia-lyase activity.
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chronic renal failure in the past but recently investigated
to prevent fatigue during strenuous exercise, as therapy
in aging-related disorders, metabolic syndrome, atopic
dermatitis, ulcers, inflammatory bowel diseases, ocular
diseases, and neurological disorders and as biomarker of
microbially-induced type II diabetes.7,8,33 These effects
are mediated by histidine and its major bioactive
metabolites histamine, N-acetylhistamine, imidazole-
4-acetate, cis-urocanate, trans-urocanate, glutamate, and
imidazole propionate.9–34,41 We developed and validated
a simple, rapid and robust method to determine their
concentrations in human and mice urine, feces and
microbiota metabolome (Figure 4 and Table 6). The
proposed method was applied to 10 human and 10 mice
FIGURE 2 UHPLC–MS/MS chromatogram of a mouse sample with HSS T3 column
TABLE 4 Analytical and statistical parameters





(ng mL1) Plof (%)
HSS T3 column
Histidine 0.018 0.027 0.03 5.20  104 99.9 0.04 1.4 4.8 12
N-acetylhistamine 0.714 0.401 0.635 7.80  103 100 0.606 0.4 1.4 44
Glutamate 0.029 0.045 0.063 8.68  104 99.9 0.067 1.5 5.2 27
Imidazole propionate 0.358 0.11 0.146 2.14  103 99.9 0.166 0.8 2.6 33
Imidazole-4-acetate 0.012 0.003 0.006 5.81  105 100 0.005 2.4 8.2 35
Histamine 0.042 0.007 0.008 1.45  104 99.9 0.011 2.3 7.8 16
BEH amide column
Cis-urocanate 0.273 0.517 0.304 1  102 99.7 0.78 0.5 1.7 17
Trans-urocanate 0.674 0.727 0.396 1.41  102 99.6 1.097 0.2 0.7 20
Notes: n, points of calibration; b, slope; sb, slope standard deviation; R
2, determination coefficient; sy/x, regression standard deviation; LOD, limit of detection;
LOQ, limit of quantification; Plof (%), probability level of the lack-of-fit test.
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samples. We also assessed production of trans-urocanate
and histamine as result of HAL and HDC activities, the
key enzymes governing histidine metabolic catabolism
(Table S3).
All metabolites were quantified in mouse feces,
suggesting broad exchange of histidine metabolites
between the gut and the host. Glutamate and histamine
were detected in all fluids and samples in concentra-
tions ranging from 0.20 to 11.78 μM for glutamate and
from 0.09 to 0.75 μM for histamine. The high frequency
of detection of these metabolites is consistent with their
central role in host metabolism and physiology. Mouse
feces had the highest glutamate content 11.78 μM, 3.3
times higher than human feces, possibly linked to differ-
ences in gut microbiota composition between species.48
Urine histamine levels in mice reached 0.75 μM, higher
than those observed in human urine that were within
previously published range.49 Differences between spe-
cies matrices was highlighted with histamine to histi-
dine urine ratio that was 281 times higher in mice
compared to humans, suggesting an underlying inflam-
matory or allergic process in our mice cohort.13 The
highest level of imidazole-4-acetate, the product of his-
tamine oxidation by diamine oxidase and aldehyde
dehydrogenase, was also observed in mouse urine, indi-
cating a high catabolic rate of histamine. Mouse urine
also contained the highest amount of imidazole propio-
nate among matrices, 10 times higher than in human
urine. Imidazole propionate showed no association with
infant health variables, possibly due to the low number
of subjects. Conversely, N-acetylhistamine could only be
quantified in human and mouse feces and in mouse
urine at concentrations from 0.11 to 0.29 μM. The fact
that N-acetylhistamine was detected in human and
mouse feces confirmed previous reports on its origin
from gut microbial metabolism50 that can eventually be
excreted in urine.51
Human urine had the highest concentration of histi-
dine reaching 7.07 μM, possibly reflecting excessive die-
tary intake of histidine rather than impaired histidine
degradation by HAL deficiency since its product trans-
urocanate was detected in all urine samples. Cis-
urocanate was effectively separated from trans-urocanate
and quantified in all matrices but mouse urine, ranging
from 0.01 μM in human feces and intracellular microbial
metabolome to 0.07 μM in human urine. This finding
likely results from UV exposure of the skin.23 Finally,
trans-urocanate reached the highest concentration
(0.62 μM) in mouse feces as observed for glutamate, both
metabolites being the initial and final intermediaries of
histidine degradation pathway (Figure 1), indicating a
high catabolic rate in mouse feces.
FIGURE 3 UHPLC–MS/MS chromatogram of a mouse sample with BEH amide column
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metabolome, and human feces
(HU, HM, and HF); and mouse
urine, mouse microbial
metabolome, and mouse feces
(MU, MM, and MF). Averages
across 10 replicates were used to
determine the histidine
metabolite contribution
TABLE 5 Accuracy of the method
Spiked (ng mL1) Founda (RSD) (ng mL1) Recovery (%)
Histidine 5 4.8 (3.2) 96
50 48.2 (1.5) 96
100 100.7 (2.8) 101
N-acetylhistamine 5 4.8 (3.8) 96
50 48.8 (0.8) 98
100 100.5 (3.5) 101
Glutamate 5 4.6 (3.9) 93
50 49.2 (2.3) 98
100 100.1 (3.1) 100
Imidazole propionate 5 4.3 (3.7) 87
50 49.4 (1.7) 99
100 99.9 (3.7) 100
Imidazole-4-acetate 5 5.7 (1.8) 114
50 49.5 (0.3) 99
100 100.5 (2.6) 101
Histamine 5 5.6 (0.8) 113
50 48.7 (1.1) 97
100 100.1 (2.6) 100
Cis-urocanate 5 4.4 (1.8) 88
50 53.7 (0.5) 107
100 98.6 (1) 99
Trans-urocanate 5 5.6 (0.3) 112
50 52.1 (1.5) 104
100 99.8 (0.7) 100
Notes: Recovery assay, precision, and trueness.
aMean determination (relative standard deviation, %).
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4 | CONCLUSIONS
A precise quantitation of alterations in the histidine metabo-
lism and its modulation by the microbiota is key to evaluate
the impact of dysbiosis in neurological, immune, and meta-
bolic diseases. Evaluation of histidine metabolites has been
covered partially by several separate methods with varying
scope, sensitivity and accuracy, preventing simultaneous
quantitation and association of metabolites and ratios with
histidine related disorders. To fill this gap, we have developed
and validated a rapid, robust, high-throughput method for
quantitation of histidine and seven bioactive metabolites eas-
ily extracted from human and mice urine, feces, and micro-
biota metabolome using liquid chromatography–tandem
mass spectrometry. Despite target compounds had different
physicochemical properties, we managed to simultaneously
measure histidine metabolites with a 6.5 min run time. Our
novel approach captures histidine metabolism in a single
assay with a high level of accuracy and reproducibility, mak-
ing it especially interesting for deep microbiota metabolic
phenotyping in large disease studies and postnatal routinely
screening of alterations in histidine pathway.
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